How can we prevent disease relapse in Graves’ orbitopathy after immunosuppressive treatment?-Reference-Cited by-同舟云学术

How can we prevent disease relapse in Graves’ orbitopathy after immunosuppressive treatment?

Published:2022-07-04 Issue:4 Volume:17 Page:269-274
ISSN:1744-6651
Container-title:Expert Review of Endocrinology & Metabolism
language:en
Short-container-title:Expert Review of Endocrinology & Metabolism

Author:

Campi Irene¹^ORCID,Fugazzola Laura¹²

Affiliation:

1. Division of Endocrine and Metabolic Diseases and Laboratory of Endocrine and Metabolic Research, Istituto Auxologico Italiano, Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy

2. Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Funder

This paper was partially supported by the Italian Ministry of Health

Publisher

Informa UK Limited

Subject

Endocrinology, Diabetes and Metabolism

Link

https://www.tandfonline.com/doi/pdf/10.1080/17446651.2022.2100344

Reference31 articles.

1. THERAPY OF ENDOCRINE DISEASE: Endocrine dilemma: management of Graves’ orbitopathy

2. Graves' Orbitopathy: Imperfect Treatments for a Rare Disease

3. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy

4. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO

5. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Efficacy of Teprotumumab in Thyroid Eye Disease: Follow-Up Outcomes in Three Clinical Trials;Thyroid®;2024-07-01

2. Statins and thyroid eye disease (TED): a systematic review;Endocrine;2024-01-09